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Cannabis is classified as a schedule I controlled substance by the US Drug Enforcement
Agency, meaning that it has no medicinal value. Production is legally restricted to a
single supplier at the University of Mississippi, and distribution to researchers is tightly
controlled. However, a majority of the population is estimated to believe that cannabis has
legitimate medical or recreational value, numerous states have legalized or decriminalized
possession to some degree, and the federal government does not strictly enforce its law
and is considering rescheduling. The explosive increase in open sale and use of herbal
cannabis and its products has occurred with widely variable and in many cases grossly
inadequate quality control at all levels—growing, processing, storage, distribution, and
use. This paper discusses elements of the analytical and regulatory system that need to
be put in place to ensure standardization for the researcher and to reduce the hazards
of contamination, overdosing, and underdosing for the end-user.
Keywords: cannabis, cannabinoids, marijuana, 19-tetrahydrocannabinol (19-THC), cannabidiol, DEA controlled
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Cannabis sativa L. is a widespread species in nature, and its use in medicine, food, textiles,
recreation, and religion dates back thousands of years. The pharmacology of its major constituent
phytocannabinoids, notably19-tetrahydrocannabinol (19-THC) and cannabidiol (CBD), has been
extensively investigated. Other pharmacologically active phytocannabinoids as well as terpenes,
flavonoids, and other constituents that may contribute to therapeutic efficacy or adverse side effects,
including abuse liability, have not been so well studied.
The United States (US) cannabis market is expected to grow to $7.1 billion in 2016, a
26% increase over 2015 (ArcView Market Research New Frontier, 2016). While the diversity
of cannabis dosage formulations and medical claims continues to increase dramatically,
there remains considerable uncertainty about phenotypes, chemotypes, naming conventions,
dosage formulation labeling accuracy, consistency, quality control, and the impact of chemical
diversity and variation in chemical composition on pharmacological or adverse effect end-
points. For instance, the Food and Drug Administration (FDA) issued several warning
letters in 2015 and again in 2016 about inappropriate and illegal medical claims for CBD
formulations manufactured or distributed by US companies. They cited instances where
the manufacturer or distributor claimed “therapeutically active” concentrations of CBD but,
upon analytical testing in FDA laboratories, no active ingredient was found. A variety
Thomas and Pollard Preparation and Distribution of Cannabis
of formulations purchased in state dispensaries failed to meet
basic label accuracy standards for pharmaceuticals. In one study,
more than 50% of products evaluated had significantly less
cannabinoid content than indicated on the label, with some
containing negligible amounts. Other products had significantly
more THC than labeled, placing patients at risk of adverse effects,
including drug interactions, and off-target effects (Vandrey et al.,
2015). In addition to inaccurate concentrations, there is concern
about the presence of other matter not listed on the label, such as
pesticides, fertilizers, fungicides, rodenticides, molds, microbes,
heavy metals, and other chemical adulterants that may be health
and environmental hazards.
Consistency in the chemical constituents of feedstock material
and finished dosage formulations is a basic requirement in
the pharmaceutical industry for quality, safety, and efficacy of
botanically derived drugs. Herbal cannabis as a manufacturing
feedstock presents a particular challenge for consistency because
it is chemically complex and variable as a result of its allogamous
nature. The chemical composition of cannabis biomass is
further affected by environment, development (age), sex, and
post-harvest processing and storage conditions. The chemical
consistency of cannabis feedstock for pharmaceuticals is best
ensured through good laboratory and agricultural practices,
including selection of appropriate female clones based on
careful analytical characterization of chemical composition,
botanical conservation, mass multiplication using advanced
biotechnological methods, and consistent harvesting and post-
processing techniques (Thomas and ElSohly, 2015). Indeed, a
variety of cannabis strains have been selected for certain physical
(phenotype) or chemical (chemotype) attributes over time, and
the processing and development of dosage formulations has
expanded dramatically, resulting in a plethora of product types
available to the recreational user, nutritional consumer, and
patient. For safe and effective use, this expanding range of
strains and formulations should be standardized and subjected
to rigorous analysis of active ingredients, impurities, and
degradants at all stages of processing and manufacturing, so
that finished drug products are characterized for homogeneity,
stability, and drug delivery over time and conditions of
anticipated storage and use.
PRODUCTION OF BOTANICAL DRUG
PRODUCTS
Many nations and US states have recently revised their regulatory
control of the production, distribution, and use of herbal
cannabis and its dosage formulations. A majority of the US
states have decriminalized some possession offenses, or legalized
recreational or medicinal use, in direct violation of existing
federal regulations. According to current federal statutes and
treaties, the bulk manufacture of cannabis and its formulations
in the US is controlled by the Drug Enforcement Administration
(DEA) in accordance with the Single Convention on Narcotic
Drugs and the Controlled Substances Act (CSA), in which
they are schedule I, the most restrictive classification. The CSA
requires the DEA to limit the number of bulk manufacturers to
the minimum required for an adequate and uninterrupted supply
of cannabis-derived substances under adequately competitive
conditions to support legitimate medical, scientific, research,
and industrial purposes [21 U.S.C. §823(a)(l)]. Under the Single
Convention, the DEA must also ensure that manufacturers are
appropriately registered and adhere to the system of controls
required by the treaty, which includes maintaining a monopoly
on the distribution of material for research. The US has
satisfied its treaty obligation through an arrangement where the
National Institute on Drug Abuse (NIDA) oversees the domestic
production and distribution of cannabis by its contractors, the
University of Mississippi and Research Triangle Institute (RTI),
respectively1. The amount manufactured by the University of
Mississippi is controlled through yearly aggregate production
quotas issued by the DEA. The DEA works with NIDA to set
the annual quota to meet research needs of the US, and may
include production of a particular strain or specific extracts or
purified natural products. DEA regulations also allow a bulk
manufacturer to maintain an inventory equal to 50% of its
average estimated net disposal for the current calendar year; these
quotas can be adjusted by the DEA.
The DEA can increase the number of entities registered as
bulk manufacturers as long as the requirements of the CSA
and Single Convention are met. These requirements include a
stipulation that the number of bulk manufacturers be kept to
the minimum required to supply authorized recipients, and thus
will not be increased until it is determined by the DEA and
NIDA that adequate amounts or varieties of plantmaterial cannot
be provided by the University of Mississippi. Any additional
registered growers would have to be acting under the direct
control of the US Government with respect to production
and distribution. Interestingly, the DEA has received only one
application by a person seeking to become a registered bulk
manufacturer to supply researchers, in addition to the University
of Mississippi, since the enactment of the CSA in 1970. The
decision by the DEA to deny the application was upheld by the
US Court of Appeals for the First Circuit in Craker v. DEA, 714
F.3d 17 (1st Cir.2013). However, in response to changing public
opinion on recreational and medicinal use and the resultant
increased demand for research, the government has acted to
expand legal production at the University of Mississippi. In 2014,
the annual amount was increased over 10-fold at the request of
NIDA, and the crop included new strains differing in their ratios
of primary phytocannabinoids.
No pesticides or herbicides are used on the crop at the
University of Mississippi, but assurances cannot be made for the
products being sold in US dispensaries. The market value is so
great that some growers use a chemical arsenal to feed and protect
the crop from microbial and animal infestation and disease to
1The lead author of this perspective (BFT) serves as the Principal Investigator on
the NIDA Drug Supply Program contract entitled “Preparation and Distribution
of Research Drug Products,” which provides for the manufacture and distribution
of cannabis dosage formulations, and as a subcontractor to the University
of Mississippi on their NIDA contract entitled “Production, Analysis and
Distribution of Cannabis, Marijuana Cigarettes, and Related Materials.” The
opinions and conclusions expressed in this publication are those of the authors
and do not necessarily reflect those of NIDA or the DEA.
Frontiers in Pharmacology | www.frontiersin.org 2 August 2016 | Volume 7 | Article 285
Thomas and Pollard Preparation and Distribution of Cannabis
realize the largest yield possible. Because the US government still
considers cannabis manufacture illegal outside of that contracted
by NIDA at the University of Mississippi, the Environmental
Protection Agency (EPA) cannot research or register pesticides,
fungicides, or herbicides for this use. However, section 24(c)
of the Federal Insecticide, Fungicide, and Rodenticide Act
(FIFRA) permits states with unique or unusual pest management
challenges to seek a special local need (SLN) registration of a
pesticide when a national registration may not be necessary or
appropriate. States that issue section 24(c) registrations must
submit them to EPA for review. The information the EPA expects
states to consider in assessing human safety and environmental
risks from application of the pesticide are described at 40
C.F.R. 162. If the EPA does not disapprove the state’s SLN
registration, distribution, and use can proceed in the registering
state with the label specifying the particular use or crop.
However, as of January 2016, the EPA had not received any SLN
registrations for cannabis. The absence of approved standards
for use, limits on chemicals types and residues, and validated
testing methods for cannabis products may result in consumer
exposure to hazardous agents or higher residue levels than
would occur if regulatory guidance and specifications existed
(Stone, 2014). Administration by smoking and inhalation may
also present greater risk of exposure with certain chemicals
compared to ingestion. Moreover, extraction and concentration
methods used for the manufacture of some dosage formulations
(tinctures, butane hash oil, “dabs”) can result in final products
containing high levels of residual solvents and pesticides, which
has been verified through residue monitoring (Raber et al., 2015),
enforcement activities, and legislative testimony (Stone, 2014).
The use of fertilizers, pesticides, herbicides, and fungicides also
poses environmental risk (Scott Nolen, 2014; Carah et al., 2015).
The consumer should recognize the potential risks from cannabis
obtained through dispensaries.
MANUFACTURE OF DOSAGE
FORMULATIONS
Rigorous quality control of feedstock and batch production
processes using good laboratory andmanufacturing practices and
validated analytical methods is required for consistency in dosage
formulation and suitability of finished product for its intended
purposes, particularly when therapeutic efficacy, and safety are
being assessed. Sampling and analytical characterizationmethods
before, during and after production are specific to the nature of
the product and its processes.
When bulk material is going to be consumed simply through
combustion or vaporization, it is still processed to some
degree. This is done because phytocannabinoid content varies
widely across the entire plant, leading to greater potential for
variance in dose, and effect. Concentration and homogeneity
can be dramatically increased when cloned, non-fertilized
female plants are grown indoors under controlled conditions,
harvested at the optimal time of flowering and senescence,
and carefully manicured to isolate the trichrome-rich flowers
(inflorescence). The inflorescence must be dried, processed,
and packaged to deter fungal and microbial growth, prevent
contamination and pest infestation, and protect the material
from light and environmental exposure. The drying process
to between 5 and 10% can be expedited by maintaining low
humidity and moderate temperature (20–40◦C) to reduce the
risk of mold while maintaining the terpene constiuents of
the inflorescence. Over extended aging time, decarboxylation
converts the phytocannabinoid acids, and terpenes isomerize to
create more complex polyterpenes with unique tastes and aromas
(Upton et al., 2013). The cannabis harvested at the University of
Mississippi for research or medical use is immediately processed,
dried, and packaged in FDA-approved polyethylene bags, and
stored in the dark at −20◦C until ready for dosage manufacture
or distribution in bulk. Researchers and patients may rehydrate
cigarettes that have been produced as NIDA dosage formulations
to increase their moisture content to between 10 and 12% before
consumption.
Dosage formulations, including cannabis cigarettes and their
placebos, cannabis tinctures, and purified cannabinoids are
available to NIH researchers. The production of large quantities
of cigarettes requires the use of a modified tobacco cigarette
manufacturing machine to produce standardized, non-filter
cannabis or placebo cigarettes of uniform weight and desired
specifications. To facilitate manufacture, the bulk plant material
needs to be processed to acceptable particle size and consistency.
Placebo material can be prepared by repeated solvent (typically
ethanol) extraction and used in bulk or in cigarette manufacture.
Alternatively, cigarettes can be manufactured from processed
cannabis in smaller scale using table-top cigarette maker
machines. Several million cigarettes in various phytocannabinoid
concentrations and placebos have been manufactured in this
way and are available for use through NIDA as medicinal
dosage formulations or for research. Extracts, tinctures, and
purified phytocannabinoid preparations have been produced
for use as requested by researchers and authorized by NIDA.
Several types of extracts and purified phytocannabinoids have
been studied. During the batch production process, through
the use of moderate heat over an extended time, the acid
forms can be isolated intact or intentionally decarboxylated to
as great an extent as possible while avoiding further thermal
decomposition to unwanted degradants. Sterile processing
and filtration can be used to manufacture formulations for
intravenous administration, and several sterile formulations have
been developed and distributed through the NIDA Drug Supply
Program (DSP). Butane hash oil and supercritical fluid extracts
are concentrated forms available at cannabis dispensaries. The
illicit manufacture of butane hash oil has been associated
with fires and severe injuries. While this formulation has
not been manufactured for use in the NIDA DSP, RTI is
developing supercritical fluid capabilities that can extract and
purify cannabis (and tobacco) constituents at the preparative
scale. Other products developed or investigated at RTI for
NIDA are oral dosage formulations in sesame oil, ethanol, and
Tween-80 for human use (Perez-Reyes et al., 1973); and edible
formulations have been produced with the help of some practical
knowledge (researchers might recall Dr. Mario-Perez Reyes’s
unpublished studies with cookies). Whatever the form, process
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control samples taken before, during, and after production
are characterized analytically to monitor physical (weight) and
chemical (phytocannabinoid concentration) parameters, and to
determine batch uniformity and other characteristics required
for the datasheets and certificates of analysis that are distributed
with the materials. All processes are reviewed by quality control
systems, and human use materials are subject to further review
and release by quality assurance systems as described in detail
below.
ANALYTICAL CHARACTERIZATION AND
STABILITY TESTING
Upon receipt of cannabis plant material for manufacture, the
biomass is quarantined in secure storage facilities approved
for schedule I use by the DEA, and conditionally released
for analytical characterization to confirm identity and potency
(strength). The raw material is sampled for homogeneity and
characterized for potency through quantitative measurement of
its most active or abundant phytocannabinoids, many of which
may be present in their biosynthetic acid or decarboxylated
forms, such as 19-THC, CBD, tetrahydrocannabivarin (THCV),
cannabinol (CBN), cannabigerol (CBG), and cannabichromene
(CBC). Limit tests must be performed for pesticides and
hazardous chemicals used in production or suspected to
be present, and the microbial burden must be adequately
assessed and controlled. Moisture content is an important
parameter affecting storage stability and processing, and other
chemical content may be measured as warranted. For example,
terpenes such as α-pinene and limonene provide characteristic
organoleptic (taste and aroma) profiles in cannabis strains,
but may also contribute to pharmacological profiles through
their actions at transient receptor potential channels or other
biochemical enzymes or substrates, including cannabinoid
receptors (β-caryophyllene is an example); hence the current
interest in terpenes.
After conditional release for manufacture, batch production
proceeds in an appropriate facility and is recorded in a
batch production record using appropriate process controls and
documented equipment calibration and performance verification
procedures. In some instances, analytical information must be
obtained before completion of processing. Time-zero samples
are taken from the final product by documented procedures,
analyzed for batch uniformity, and stored in qualified stability
chambers or storage facilities where temperature and humidity
are monitored and controlled over varying storage times.
Critical performance specifications for dosage formulations are
tested and documented on datasheets supplied to researchers,
such as weight, potency, and unique parameters for particular
formulations. Cigarette smoke yields can be assessed by validated
smoking machines. All analytical data and other documentation
are reviewed by an independent quality control chemist and
by quality assurance people prior to release, with each product
accompanied by its informational datasheets. All materials within
the NIDA DSP are also subject to intermittent quality control
analysis over time to ensure suitability for use. In some instances,
materials, or formulations may need to be purified periodically.
Distribution to researchers can occur within a few days of
shipment authorization, though some instances may require 2–3
weeks to meet a researcher’s individual needs.
DISTRIBUTION OF CANNABINOID
DOSAGE FORMULATIONS
Researchers who wish to do studies with cannabis must have a
special DEA registration under the CSA [21 U.S.C. § 823(f) and
21 CFR 1301.18 and 1301.32]. Application is submitted on DEA
Form-225 for the appropriate schedule I drug code, along with a
1-year registration fee, a research protocol showing the amount
of drug needed, and a copy of the researcher’s curriculum vitae.
Upon receipt of the application, a DEA investigator conducts a
site visit to verify that security procedures and diversion controls
are adequate for storage and use. TheDEA also sends the research
protocol to the FDA for review and approval. The researcher
might also need to register with state and local agencies and
comply with their regulations for schedule I.
US researchers with NIH grant funding submit a request
to NIDA’s DSP along with a copy of their DEA registration, a
completed DEA Form-222, and other required documentation
about funding and intended use. Investigators who desire
access to human use material from the DSP must also have
documentation of local institutional review board approval and
an active Investigational New Drug Application (IND) for the
conduct of clinical studies that has been evaluated and found safe
by the FDA. NIDA has compiled a DrugMaster File that provides
the FDA with information on seed selection, growth, harvesting,
manufacturing, analytical characterization, and stability testing
for each batch of its cannabis and formulations, which can be
referenced in the IND to facilitate use in human subjects. If
the material is to be used for non-clinical human research, the
request is simply forwarded to NIDA’s Office of the Director for
review and recommendation. Researchers without an NIH grant
are subject to additional scientific review. Foreign applicants
must provide documentation that controlled substances, research
chemicals, or cannabis cigarettes being requested are permitted
for import into their countries.
When NIDA approves and authorizes the distribution of
a schedule I controlled substance to a researcher or patient,
materials are released, packaged, and distributed for use in
preclinical and clinical studies or for medicinal use under the
Compassionate Use Act. A barcode-based electronic inventory
management system tracks every batch, providing independent,
automated verification of all compound supplies, allocations,
and distributions. Release of materials classified as “Animal
Use” or “Other” is based on examination and verification that
they are exactly as described in the authorizing documents;
this is checked by a second person, noted on the shipment
document, and checked again by the person who packages the
shipment. Materials classified as “Human Use” require release
by quality assurance staff, who are responsible for oversight of
all processes involved with human-use materials to ensure good
practice quality guidelines and regulations (GxP) compliance.
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Each batch has a certificate of analysis or a data sheet that is
provided to the researcher or end user containing information
on the particular batch along with recommendations for its
proper handling, storage, and use. Packaging must comply
with federal code and is customized to minimize extremes of
temperature and provide maximum protection against breakage,
contamination, and loss. When refrigeration is required, material
may be shipped on cold packs at −20 or on dry ice at
−70◦C.
From the time a researcher submits a request to NIDA, the
entire review, authorization, shipment preparation, release, and
distribution can typically be done within 2–4 weeks. Formaterials
to be exported, an export permit must be obtained from the
DEA and an import permit from the destination country for
each shipment, along with a statement that the drugs will not
be re-exported. If all of these documents are found by the DEA
to be correct, an export permit will typically be issued in 2–3
weeks.
THE EVOLVING ROLE OF THE DEA, NIDA,
AND FDA IN CANNABINOID RESEARCH
Medicinal and recreational users and research investigators often
desire access to higher potency materials and more varieties
of cannabis and cannabinoid dosage formulations than are
currently available through NIDA (Russo et al., 2002; Stith
and Vigil, 2016), and efforts to address these unmet needs are
ongoing (Reardon, 2015). However, the limitations in the NIDA
DSP inventory are compounded by the rapid proliferation
of cannabis varieties, cannabis-derived formulations (e.g.,
lipstick, creams, sunscreen, edibles, and drinks), and routes of
administration (dermal, vaporization, and inhalation). Many
of these products that are commercially available on the illicit
market or in state dispensaries are not sufficiently characterized
to enable distribution to researchers through the NIDA drug
supply program. Thus, NIDA cannabis and cannabis-derived
products may not be representative of cannabis in commerce,
whether intended for recreational or therapeutic use (see Bloor
et al., 2008; Shen, 2014; ElSohly et al., 2016, for example).
Moreover, while polls suggest that most people believe cannabis
has therapeutic utility and should not be schedule I, the DEA
has rejected rescheduling petitions several times in the past;
most recently in August of 2016. Rescheduling would enable
doctors to prescribe cannabis and cannabis-derived botanical
drugs as therapeutics. It would also facilitate research by
professionals to investigate the basic science of cannabis, and to
use this information to better understand neurophysiological
function, develop new medicines for people and animals,
and find improved ways to deal with abuse. Rescheduling
or de-scheduling might also decrease the abuse of the novel
psychoactive synthetic cannabinoids that have been sold as legal
“incense,” and that pose significant health risks and challenges
for detection of use. Thus, the current status of cannabis use in
the US continues to present unique policy, regulatory, criminal
justice, financial, and research concerns that can only be legally
addressed with the assistance and support of the DEA, NIDA,
and the FDA. Working together, these agencies, along with
researchers, physicians, patients, and industry stakeholders, can
help ensure the proper manufacture, labeling, and distribution
of safe and consistent products with known chemical content
and well-characterized performance. More information on
access to cannabis can be obtained from NIDA (https://www.
drugabuse.gov/researchers/research-resources/nida-drug-supply-
program), the DEA (https://www.dea.gov/divisions/hq/
2016/hq081116.shtml), and the FDA (http://www.fda.gov/
NewsEvents/PublicHealthFocus/ucm421168.htm).
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